Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [1409]

ASCO 2020: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumours

ASCO 2020: Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid...

ASCO 2020: Combined cediranib and olaparib presents similar activity to standard of care treatment

ASCO 2020: Combined cediranib and olaparib presents similar activity to standard of care treatment

ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions

ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions

ASCO 2020: Immunotherapy avelumab shows potential in rare gynaecological cancer resistant to chemotherapy

ASCO 2020: Immunotherapy avelumab shows potential in rare gynaecological cancer resistant to chemotherapy

Personalised ovarian cancer risk prediction reduces worries

Personalised ovarian cancer risk prediction reduces worries

Study confirms important clues to fight ovarian cancer

Study confirms important clues to fight ovarian cancer

Cervical precancer identified by fluorescence, in a step toward bedside detection

Cervical precancer identified by fluorescence, in a step toward bedside detection

ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with relapsed ovarian cancer and BRCA mutation

ASCO 2020: Maintenance therapy With PARP inhibitor olaparib extends survival by over 1 year in patients with...

Cervical cancer screening during the COVID-19 Crisis: Africa view point

Cervical cancer screening during the COVID-19 Crisis: Africa view point

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal...

More from ecancer